Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Completed · Phase 4

Conditions studied: Hyperglycemia, Diabetes

In brief

The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design. Note: Lantus insulin is the proprietary name for glargine insulin.

Key facts

Study ID

NCT00338104

Run by

Northwestern University

People needed

75

Starts

2004-07-01

Expected to finish

2005-05-01

Last updated by the study team

2009-04-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fasting glucose > 100 mg/dl
• Patients on surgical services or in intensive care units receiving intravenous insulin

You may not qualify if…

• Inability to obtain informed consent from patient or next-of-kin
• Allergy to insulin
• Participation in another research study
• Patients for whom there are "do-not-resuscitate" orders

Where it is running

• Northwestern Memorial Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.